Gerald Proehl, president and chief executive officer, said that the IND filing is an important milestone in the rifamycin SV MMX clinical programme, and the company looks forward to moving forward with the development of rifamycin SV MMX for patients with travelers' diarrhea
Your type of travel, the season, the precautions you take to prevent it, and your children's ages can also affect your risk of getting travelers' diarrhea
In several studies, antimotility agents have been useful in treating travelers' diarrhea
by decreasing the duration of diarrhea.
A 500-mg dose of the antibiotic along with the antimotility agent, taken immediately after the first loose stool, often can preempt a full-bore bout of travelers' diarrhea
Falk Pharma GmbH, Cosmo's European development partner, is conducting a second Phase III clinical study to evaluate the efficacy of rifamycin SV MMX versus ciprofloxacin with the primary endpoint of TLUS in patients with travelers' diarrhea
She wonders what she might do to prevent travelers' diarrhea
Rifamycin SV has also demonstrated a broad spectrum of in vitro activity targeted to the main enteropathogens that cause travelers' diarrhea
Information for health care providers: travelers' diarrhea
In the IND, Santarus proposed two international multicenter, randomized, double-blind studies, each with approximately 300 patients, to assess the efficacy and safety of rifamycin SV MMX 400 mg (2 x 200 mg) oral tablets taken twice daily (800 mg total daily dose) for three days versus placebo in the treatment of patients with travelers' diarrhea
The United States Centers for Disease Control and Prevention (CDC) state that travelers with nausea, vomiting, cramps, fever, or blood in stools may benefit from treatment for travelers' diarrhea
with ciprofloxacin (500 mg twice daily) or trimethoprim-sulfamethoxazole (double-strength tablet twice daily) for 3 days.
is infectious diarrhea caused by the ingestion of contaminated food or water by travelers usually in a developing country.
Nasdaq:OPTR) today announced positive results from the second of two double-blind pivotal Phase 3 trials assessing the safety and efficacy of Prulifloxacin as a once-daily (600 mg), three-day oral therapy for the treatment of infectious diarrhea, including travelers' diarrhea